Drugs / GC301
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06391736 | Apr 2024 → Dec 2026 expected | glycogen storage disease due to acid maltase deficiency, late-onset | GeneCradle Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05793307 | Jun 2023 → Dec 2025 overdue | glycogen storage disease due to acid maltase deficiency, infantile onset | GeneCradle Inc | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05567627 | Aug 2022 → Sep 2024 | glycogen storage disease due to acid maltase deficiency, infantile onset | Seventh Medical Center of PLA General Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-08-29 | AbClon | Results 앱클론 “AC101, 글로벌 임상 3상 확장...전이성 위암 1차 치료제 넘어 유방암까지” abclon.com ↗
또한 중앙추적관찰기간 28.5개월 시점에서 무진행생존기간과 전체생존기간, 반응 지속기간 모두 기존 표준치료보다 뛰어난 결과를 보였다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-08-29 | AbClon | 앱클론 “AC101, 글로벌 임상 3상 확장...전이성 위암 1차 치료제 넘어 유방암까지” abclon.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06391736 ↗ |
| Action | Restore | “delivering a functional copy of the human GAA gene” NCT05567627 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “adeno-associated virus 9 (AAV9) vector” NCT05567627 ↗ |
| Route | Intravenous | “GC301 administered via intravenous infusion” NCT05567627 ↗ |
| Target | GAA | “functional copy of the human GAA gene” NCT05567627 ↗ |